Frontiers in antibiotics · 2026
Longitudinal trends in antimicrobial resistance phenotypes in Pseudomonas aeruginosa: a seven-year study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alghamdi Wael A, Orayj Khalid M, Ibrahim Ahmed R N, Abdelsalam Marim A, Alshehri Abdullah M
Аннотация
BACKGROUND: Pseudomonas aeruginosa is a major cause of healthcare-associated infections and is increasingly associated with antimicrobial resistance. Continuous local surveillance is essential to monitor evolving resistance patterns and inform empirical antimicrobial therapy and antimicrobial stewardship.
METHODS: This retrospective laboratory-based surveillance study analyzed non-duplicate P. aeruginosa isolates recovered from hospitalized patients at a secondary healthcare setting in Saudi Arabia between 2018 and 2024. Resistance phenotypes were classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat resistance (DTR) according to established international definitions. Temporal trends were evaluated using logistic regression.
RESULTS: A total of 368 non-duplicate P. aeruginosa isolates were included. Respiratory tract specimens were the most common source of isolates. MDR prevalence increased from 51.0% in 2018 to a peak of 87.3% in 2022 before declining to 69.6% in 2024, while XDR reached its highest prevalence of 68.3% in 2023 before declining to 39.1% in 2024. When year was analyzed categorically, significant differences across years were observed for MDR (P < 0.001) and XDR (P = 0.003), but not DTR (P = 0.144).
CONCLUSION: This seven-year surveillance study demonstrated a substantial burden of antimicrobial resistance among P. aeruginosa isolates, with significant year-to-year variation in MDR and XDR prevalence. These findings provide locally relevant surveillance data that may inform empirical antimicrobial therapy, antimicrobial stewardship, and ongoing institutional resistance surveillance.
METHODS: This retrospective laboratory-based surveillance study analyzed non-duplicate P. aeruginosa isolates recovered from hospitalized patients at a secondary healthcare setting in Saudi Arabia between 2018 and 2024. Resistance phenotypes were classified as multidrug-resistant (MDR), extensively drug-resistant (XDR), and difficult-to-treat resistance (DTR) according to established international definitions. Temporal trends were evaluated using logistic regression.
RESULTS: A total of 368 non-duplicate P. aeruginosa isolates were included. Respiratory tract specimens were the most common source of isolates. MDR prevalence increased from 51.0% in 2018 to a peak of 87.3% in 2022 before declining to 69.6% in 2024, while XDR reached its highest prevalence of 68.3% in 2023 before declining to 39.1% in 2024. When year was analyzed categorically, significant differences across years were observed for MDR (P < 0.001) and XDR (P = 0.003), but not DTR (P = 0.144).
CONCLUSION: This seven-year surveillance study demonstrated a substantial burden of antimicrobial resistance among P. aeruginosa isolates, with significant year-to-year variation in MDR and XDR prevalence. These findings provide locally relevant surveillance data that may inform empirical antimicrobial therapy, antimicrobial stewardship, and ongoing institutional resistance surveillance.